Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis

INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barrier to adherence in patients with haemophilia. An extended half-life fusion protein linking recombinant FIX (rFIX) with human albumin (rIX-FP) has been developed for the treatment of patients with haem...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermans, Cedric, Marino, Renato, Lambert, Catherine, Mangles, Sarah, Sommerer, Patrick, Rives, Vincent, Maro, Geraldine, Malcangi, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467451/
https://www.ncbi.nlm.nih.gov/pubmed/32333327
http://dx.doi.org/10.1007/s12325-020-01300-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467451/
https://www.ncbi.nlm.nih.gov/pubmed/32333327
http://dx.doi.org/10.1007/s12325-020-01300-6

Ejemplares similares